Active Microfluidic Separation (AMS) is a mass-producable technology for medical diagnostics and therapy, simplifying research and laboratory life.
INNOVATION FORUM 23. Sep. – 24. Sep. 2021

Ultra-pure fractionation of organic and inorganic particles out of liquids

Can be used in the laboratory or directly at the point-of-care (POC) enabling diagnostics and therapeutic applications

Initiation of cooperations between potential medical users like physicists or biochemists and developers of AMS technology

A partnership between Leibniz Institute for Solid State and Materials Research Dresden and innovation consultancy INNOcentric GmbH

Faster | Cheaper | smaller

The quick & easy, cost-effective technology delivers lightning-fast results, compared to conventional separation technologies such as ultra-centrifugation.
A modular lab-on-a-chip kit can be realized in micro format for common price ranges comparable to semi-conductor technologies.


faster processes


reduced operating and material costs


reduced investment

In the lab, AMS technology competes with classical Density Gradient Centrifugation or Dielectrophoresis, as no more time-consuming preparations have to be made. The time saved lab personnel can devote to other important tasks.


Active Microfluidic Separation (AMS) is a technology enabling high-purity sorting of organic (cells, biomolecules) or inorganic (magnetic beads, bio-markers) elements.

Particles can be sorted by size from media such as blood, urine, saliva, sweat, cerebrospinal fluid or from cell culture supernatants such as substances grown in bioreactors, stirred reactors or Petri dishes, into their constituents on a micro scale.

Passive microfluidic components based on filters or hydrodynamic processes cannot achieve such purification or cell separation results in the required quality.

Precise Selection Quality

Precise selection quality

Today, it is already possible to separate 1 µm to 30 μm particles in a flow-through process at the point of care.

Experiments to separate 100 nm to 100 μm sized particles are currently underway.


Integrable Technologies

Bio-chips allow modular integrations of other microtechnologies via common hardware and software interfaces according to Good Manufacturing Practice (GMP). This enables a wide range of applications for integratable technologies such as microspectroscopic examination or diagnosis using semiconductor-based assays.

Medical quality guidelines do not allow external purification (sample preparation) for immediate in-vitro diagnostics, which is why the approach of heterointegration in one system brings medical benefits.

in the focus of the frame is a drop of medicine hanging on the injection needle of the syringe, in the background is not in the depth of field a syringe and an ampoule with injection liquid

Reduced Sample Sizes

Around 50µL are sufficient to form fractions from cells, bacteria or extracellular vesicles.

Sample volumes of a few microliters extend the range of applications to scarce liquids such as cerebrospinal fluid.

Application Areas

Active Microfluidic System

Lab-on-a-Chip Operations

Diagnostics and
MedTech Technology

MedTech Applicators

Operational Scenarios

In discussions with around twenty experts, a number of topics have already emerged that are worth discussing at the forum:

  • Separation of erythrocytes, leukocytes and platelets from whole blood using acoustofluidic separation. This method has already been validated with one of the largest German blood donation services (learn more here)
  • Purification of leukocytes with subsequent cell analysis and subsequent sorting out of selected single cells.
  • Separation of extracellular vesicles (cell debris and exosomes).
Diagnostic and therapeutic approaches are also conceivable:
10274587 - doctor with hightech computer screen viewing patient data


The aim is to bring established diagnostics from the lab to the patient. For this purpose, a downscaling of existing analytics to microscale with at least the same quality is aimed at.

This means that samples do not have to travel long distances to the laboratory to be purified and analyzed at great expense.

This is why downstream microfluidic analysis on the patient is also addressed, because a rapid diagnosis can be a life-saving measure for the patient.


Pre- or Post-selection of Cells in research or laboratory

Simplifies processes for microbiologists in research. By accurately pre-selecting or post-selecting cells, new biomarkers can be used for validation, or certain cells can serve directly as assays.

63473976 - artificial insemination process

Gene- and Single-Cell-Therapeutics

Single-cell analysis and manipulation offer completely new application scenarios, e.g. in gene therapy, which are not yet possible today, or at least only with significantly greater effort and much less precision.

The separation of single cells opens up new ways for stem cell or immuno-therapies. The cost-effective purification in a flow-through process makes therapies in hematology or hemato-oncology particularly attractive.

Innovation Forum

September 23th - 24th 2021 in Leipzig


The aim of the AMS Innovation Forum is to create and strengthen networks between commercial providers of microfluidic technologies for cell separation and developers of innovative diagnostic and therapeutic procedures in order to develop qualitatively better, faster and more cost-effective procedures for tomorrow’s medicine.

Microfluidics has great potential for accelerating and simplifying diagnostic and cell-based therapeutic procedures, because it saves time and expense of central laboratories and their logistics. Single-cell analysis and manipulation offer completely new application scenarios, e.g. in gene therapy, which are not yet possible today, or at least only with significantly greater effort and much less precision.

Our Way to your Goal

1. In preparation workshops we find out possible use-cases with you.

2. Presentation of the current discussions, solution approaches and challenges in an innovation forum in September. There representatives from the microfluidic-branch and applicators from the Point-of-Care take your questions and discuss with you.

3. Afterwards we elaborate commercialization strategies, build up possible syndicates or StartUps.

The program will be in German only.

Day 1

12:30 Start of the event

13:00 Keynotes: Tech2Med meets Med2Tech

14:00 Pitchsessions

16:15 Coordinated 1:1 speeddatings

18:00 End of the 1st day

19:30 Dinner event at one of the most beautiful locations in Leipzig


Day 2

09:00 Greetings and talk about fundraising in MedTech

09:20 Cooperation workshops in small groups

12:15 Lunch break and networking

13:00 Optional: Discussion about the further steps

15:00 End of the event and departure

*The program is continuously adapted to the participants (as of 15.06.2021)

Hier registrieren (Klick)



23.09.2021 – 24.09.2021


Park Hotel Leipzig
Richard-Wagner-Str. 7
04109 Leipzig


The Park Hotel Leipzig is offering single and double beds for 90€ to 105€. Please use the following link or the booking code: INNOcentric. The allotment will be available until 23.08.2021.


Free of charge


Peter Häfner
Cooperation Development
| Project and Innovation Management and Funding

INNOcentric GmbH

Dr. Stefanie Hartmann
Business Modelling Acoustofluidics
| Business Development

Leibniz Institute for Solid State and Materials Research

Dr. Andreas Winkler
Technology Acoustofluidics
| Product development

Leibniz Institute for Solid State and Materials Research

Sascha Mühl
Cooperation Development
| Partnering Diagnostics and Innovation Management

INNOcentric GmbH

Become a Partner

Interested? Become a partner and register here in advance!

Who can become a partner?
In addition to providers of microfluidic technologies, two focus groups will be targeted:

Developer and producer of clinical diagnostic devices as integrators: Developers of analytics from industrial companies, established start-ups or applied research institutes, who

  • want to integrate separation technologies in the upstream or downstream or
  • need cell excitation
  • offer or research active bio-chips in medical analytics (e.g. sensor technology)

End-User as a key person – revealing a problem:
Physician, application oriented researchers, micro biologists, bio-chemists seeking for

  • purification or separation solutions for a specific field of application and still face unsolved problems,
  • have experience or interest in chip-based analysis of liquid or liquefied body media.

Submit your problem and associated challenge in advance.